- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- S-1 IPO registration
- 2.1 EX-2.1
- 3.1 EX-3.1
- 3.2 EX-3.2
- 3.3 EX-3.3
- 3.4 EX-3.4
- 3.5 EX-3.5
- 3.6 EX-3.6
- 3.7 EX-3.7
- 3.8 EX-3.8
- 3.9 EX-3.9
- 3.10 EX-3.10
- 4.1 EX-4.1
- 4.2 EX-4.2
- 10.1 EX-10.1
- 10.2 EX-10.2
- 10.3 EX-10.3
- 10.4 EX-10.4
- 10.5 EX-10.5
- 10.6 EX-10.6
- 10.7 EX-10.7
- 10.8 EX-10.8
- 10.9 EX-10.9
- 10.10 EX-10.10
- 10.11 EX-10.11
- 10.12 EX-10.12
- 10.13 EX-10.13
- 10.14 EX-10.14
- 10.15 EX-10.15
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.21 EX-10.21
- 10.22 EX-10.22
- 10.23 EX-10.23
- 10.24 EX-10.24
- 10.25 EX-10.25
- 10.26 EX-10.26
- 10.27 EX-10.27
- 10.28 EX-10.28
- 10.29 EX-10.29
- 10.30 EX-10.30
- 10.31 EX-10.31
- 10.32 EX-10.32
- 10.33 EX-10.33
- 10.34 EX-10.34
- 10.35 EX-10.35
- 10.36 EX-10.36
- 10.37 EX-10.37
- 10.38 EX-10.38
- 10.39 EX-10.39
- 10.40 EX-10.40
- 10.41 EX-10.41
- 10.42 EX-10.42
- 10.43 EX-10.43
- 10.44 EX-10.44
- 10.45 EX-10.45
- 10.46 EX-10.46
- 10.47 EX-10.47
- 10.48 EX-10.48
- 10.49 EX-10.49
- 10.50 EX-10.50
- 10.51 EX-10.51
- 10.52 EX-10.52
- 10.53 EX-10.53
- 10.54 EX-10.54
- 10.55 EX-10.55
- 10.56 EX-10.56
- 10.57 EX-10.57
- 10.58 EX-10.58
- 10.59 EX-10.59
- 10.60 EX-10.60
- 10.61 EX-10.61
- 10.62 EX-10.62
- 10.63 EX-10.63
- 10.64 EX-10.64
- 10.65 EX-10.65
- 10.66 EX-10.66
- 10.67 EX-10.67
- 10.68 EX-10.68
- 10.69 EX-10.69
- 10.70 EX-10.70
- 10.71 EX-10.71
- 10.72 EX-10.72
- 10.73 EX-10.73
- 10.74 EX-10.74
- 10.75 EX-10.75
- 10.76 EX-10.76
- 10.77 EX-10.77
- 10.78 EX-10.78
- 10.79 EX-10.79
- 10.80 EX-10.80
- 10.81 EX-10.81
- 10.82 EX-10.82
- 10.83 EX-10.83
- 10.84 EX-10.84
- 10.85 EX-10.85
- 10.86 EX-10.86
- 10.87 EX-10.87
- 10.88 EX-10.88
- 10.89 EX-10.89
- 10.90 EX-10.90
- 10.91 EX-10.91
- 10.92 EX-10.92
- 10.93 EX-10.93
- 10.94 EX-10.94
- 21 EX-21
- 23.1 EX-23.1
- Download Excel data file
- View Excel data file
- 19 Feb 21 424B3 Prospectus supplement
- 8 Feb 21 424B3 Prospectus supplement
- 1 Dec 20 424B3 Prospectus supplement
- 24 Nov 20 424B3 Prospectus supplement
- 29 Oct 20 EFFECT Notice of effectiveness
- 28 Oct 20 424B3 Prospectus supplement
- 26 Oct 20 S-1/A IPO registration (amended)
-
14 Oct 20 S-1 IPO registration
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement on Form S-1 of RespireRx Pharmaceuticals Inc. (the “Company”) of our report dated April 14, 2020, relating to our audit of the Company’s consolidated financial statements as of and for the years ended December 31, 2019 and 2018. Our report contains an explanatory paragraph that states the Company has experienced losses, negative cash flows from operations, has limited capital resources, and a net stockholders’ deficiency. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
We also consent to the reference to our Firm under the heading “Experts” in this Registration Statement on Form S-1.
/s/ Haskell & White LLP | |
Haskell & White LLP | |
Irvine, California | |
October 13, 2020 |